Aktienanalyse zu Praxis Precision Medicines Inc (PRAX)PRAXPraxis Precision Medicines Inc

Praxis Precision Medicines, Inc. is an integrated, central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company's product candidates include Ulixacaltamide, Vormatrigine, Relutrigine, PRAX-080, Elsunersen, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Praxis Precision Medicines Inc (PRAX) is currently not a good buy due to its low RSI of 19.357, indicating oversold conditions, and a significant recent decline of 12.06% over the last five days. While analysts have set price targets significantly higher than the current price of $259.86, the company is facing substantial losses, with a net income of -92561000 USD expected in Q1 2026. The main risk is the ongoing negative earnings trend, as evidenced by a forward P/E ratio of 0 and a price-to-sales ratio of 985.97, suggesting the stock is highly overvalued based on current revenue performance.